Literature DB >> 15189934

Treatment costs of community-acquired pneumonia in an employed population.

Gene L Colice1, Melissa A Morley, Carl Asche, Howard G Birnbaum.   

Abstract

BACKGROUND: Community-acquired pneumonia (CAP) is a serious clinical problem, causing hospitalization in about 20% of cases and death in up to 16% of hospitalized patients. Work-loss cost estimates indicate that the treatment of CAP also has a large economic impact. The purpose of this study was to assess the medical and prescription drug (treatment) costs of managing CAP in an employed population.
METHOD: The costs of CAP were determined from an administrative claims database covering the years 1996 to 1998 for an employed population and their dependents [65 years of age (100,000 population)]. Treatment costs for managing both inpatient and outpatient cases of CAP were calculated from payments by the health plan.
RESULTS: A total of 7,249 episodes of CAP among 6,415 individuals were identified. The hospitalization rate was 19.6%, and the mortality rate for those hospitalized was 9.1%. Patients requiring hospitalization were older and had more comorbid conditions. The mean (+/- SD) treatment cost for an inpatient episode of CAP (including all inpatient and outpatient medical care) was $10,227 +/- 15,342. The costs for inpatients who died during hospitalization (mean cost, $15,822 +/- 26,541) were higher than for episodes in which patients were discharged from the hospital alive (mean cost, $9,595 +/- 13,641). The mean treatment cost for an outpatient episode of CAP was $466 +/- 1,038.
CONCLUSIONS: The treatment cost of managing CAP in this employed population was higher than previously estimated. It is estimated that the annual cost of treating CAP in the United States is $12.2 billion.

Entities:  

Mesh:

Year:  2004        PMID: 15189934     DOI: 10.1378/chest.125.6.2140

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.

Authors:  H W Choi; K Miele; D Dowdy; M Shah
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

2.  Poor clinical outcomes among pneumonia patients with schizophrenia.

Authors:  Yi-Hua Chen; Hsiu-Chen Lin; Herng-Ching Lin
Journal:  Schizophr Bull       Date:  2010-03-25       Impact factor: 9.306

3.  CURB-65 score predicted mortality in community-acquired pneumonia better than IDSA/ATS minor criteria in a low-mortality-rate setting.

Authors:  Q Guo; H-Y Li; Y-P Zhou; M Li; X-K Chen; H Liu; H-L Peng; H-Q Yu; X Chen; N Liu; L-H Liang; Q-Z Zhao; M Jiang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-18       Impact factor: 3.267

Review 4.  Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers.

Authors:  Shawn A N Gilchrist; Angeline Nanni; Orin Levine
Journal:  Am J Public Health       Date:  2012-02-16       Impact factor: 9.308

5.  Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.

Authors:  Nathan C Dean; Paul Sperry; Matthew Wikler; Mary S Suchyta; Carol Hadlock
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  [Incidence rate of community acquired pneumonia in a population cohort registered in BIFAP].

Authors:  Ana Chacón García; Ana Ruigómez; Luis Alberto García Rodríguez
Journal:  Aten Primaria       Date:  2010-09-15       Impact factor: 1.137

7.  Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.

Authors:  Christopher R Frei; Matthew J Labreche; Russell T Attridge
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

8.  Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong.

Authors:  Shin Yan Man; Nelson Lee; Margaret Ip; Gregory E Antonio; Shirley S L Chau; Paulina Mak; Colin A Graham; Mingdong Zhang; Grace Lui; Paul K S Chan; Anil T Ahuja; David S Hui; Joseph J Y Sung; Timothy H Rainer
Journal:  Thorax       Date:  2006-11-22       Impact factor: 9.139

9.  Trends in mortality and medical spending in patients hospitalized for community-acquired pneumonia: 1993-2005.

Authors:  Gregory W Ruhnke; Marcelo Coca-Perraillon; Barrett T Kitch; David M Cutler
Journal:  Med Care       Date:  2010-12       Impact factor: 2.983

10.  The incidence rate and economic burden of community-acquired pneumonia in a working-age population.

Authors:  Jonah Broulette; Holly Yu; Bruce Pyenson; Kosuke Iwasaki; Reiko Sato
Journal:  Am Health Drug Benefits       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.